Nikhil Yegya-Raman, MD
Assistant Professor of Clinical Radiation Oncology
Chief Resident, University of Pennsylvania, Department of Radiation Oncology
Department: Radiation Oncology
Contact information
Pennsylvania Hospital
800 Spruce Street
Philadelphia, PA 19107
800 Spruce Street
Philadelphia, PA 19107
Education:
AB (Chemistry, High Honors; Certificate in Engineering Biology)
Princeton University, 2014.
MD
Rutgers Robert Wood Johnson Medical Scool, 2019.
Permanent linkAB (Chemistry, High Honors; Certificate in Engineering Biology)
Princeton University, 2014.
MD
Rutgers Robert Wood Johnson Medical Scool, 2019.
Selected Publications
Yegya-Raman N, Berman AT, Ciunci CA, Friedes C, Berlin E, Iocolano M, Wang X, Lai C, Levin WP, Cengel KA, O’Reilly SE, Cohen RB, Aggarwal C, Marmarelis ME, Singh AP, Sun L, Bradley JD, Plastaras JP, Simone CB 2nd, Langer CJ, Feigenberg SJ: Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 119(1): 56-65, May 2024.Yegya-Raman N, Friedes C, Lee SH, Iocolano M, Duan L, Wang X, Li B, Aggarwal C, Cohen RB, Su W, Doucette A, Levin WP, Cengel KA, DiBardino D, Teo BKK, O’Reilly SE, Sun L, Bradley JD, Xiao Y, Langer CJ, Feigenberg SJ: Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation. Int J Radiat Oncol Biol Phys 118(5): 1445-1454, Apr 2024.
Friedes C, Iocolano M, Lee SH, Li B, Duan L, Levin WP, Cengel KA, Sun LL, Aggarwal C, Marmarelis ME, Doucette A, Cohen RB, Xiao Y, Langer CJ, Bradley J, Feigenberg SJ, Yegya-Raman N: Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys 118(5): 1435-1444, Apr 2024.
Anstadt EJ, Carmona R, Berlin E, Yegya-Raman N, Venigalla S, Reddy V, Williams GR, Leibensperger MR, Wojcieszynski A, Baumann BC, Lee MK, Plastaras JP, Furth EE, Mell LK, Metz JM, Ben-Josef E: SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma. Cancer 130(3): 476-484, Feb 2024.
Iocolano M, Yegya-Raman N, Friedes C, Wang X, Kegelman T, Lee SH, Duan L, Li B, Levin WP, Cengel KA, Konski A, Langer CJ, Cohen RB, Sun L, Aggarwal C, Doucette A, Xiao Y, Kevin Teo BK, O'Reilly S, Zou W, Bradley JD, Simone CB 2nd, Feigenberg SJ: Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era. Cancer Jan 2024 Notes: Online ahead of print.
Friedes C, Feigenberg SJ, Yegya-Raman N: Patterns of Failure after PACIFIC: How to Address Disease Recurrence after Chemoradiotherapy and Immunotherapy. International Association for the Study of Lung Cancer (IASLC) Lung Cancer News Jan 2024 Notes: https://www.ilcn.org/patterns-of-failure-after-pacific-how-to-address-disease-recurrence-after-chemoradiotherapy-and-immunotherapy/
Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci C, Singh AP, D’Avella C, Davis C, Langer CJ, Feigenberg SJ: Patterns of failure in metastatic non-small cell lung cancer treated with first line pembrolizumab and use of local therapy in patients with oligoprogression. Clin Lung Cancer 25(1): 50-60, Jan 2024.
Friedes C, Iocolano M, Lee SH, Duan L, Li B, Doucette A, Cohen RB, Aggarwal C, Sun LL, Levin WP, Cengel KA, Kao G, Teo BK, Langer CJ, Xiao Y, Bradley J, Feigenberg SJ, Yegya-Raman N: The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC. Radiother Oncol 190: 110030, Jan 2024.
Yegya-Raman N, Ho Lee S, Friedes C, Wang X, Iocolano M, Kegelman TP, Duan L, Li B, Berlin E, Kim KN, Doucette A, Denduluri S, Levin WP, Cengel KA, Cohen RB, Langer CJ, Kevin Teo BK, Zou W, O'Quinn RP, Deasy JO, Bradley JD, Sun L, Ky B, Xiao Y, Feigenberg SJ: Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother Oncol 190: 110005, Jan 2024.
Arkles J, Markman T, Trevillian R, Yegya-Raman N, Garg L, Nazarian S, Santangeli P, Garcia F, Callans D, Frankel DS, Supple G, Lin D, Riley M, Kumaraeswaran R, Marchlinski F, Schaller R, Desjardins B, Chen H, Apinorasethkul O, Alonso-Basanta M, Diffenderfer E, Kim MM, Feigenberg S, Zou W, Marcel J, Cengel KA: One-year outcomes after stereotactic body radiotherapy for refractory ventricular tachycardia. Heart Rhythm 21(1): 18-24, Jan 2024.